Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Mark Sausen(Human Genome Sciences (United States)), Victor E. Velculescu(Johns Hopkins University), David S. Klimstra(Yale University), Rebecca Leary(Howard Hughes Medical Institute), Peter J. O’Dwyer(University of Pennsylvania), Anirban Maitra(NYU Langone Health), James R. White(Resphera Biosciences), Luis A. Díaz(Memorial Sloan Kettering Cancer Center), Rob Scharpf(Johns Hopkins University), Craig B. Thompson(Memorial Sloan Kettering Cancer Center), Valsamo Anagnostou(Johns Hopkins University), James R. Eshleman(Johns Hopkins University), Carolyn Hruban(Johns Hopkins University), Julia S. Johansen(ScienceScope (United Kingdom)), Derek Murphy(Human Genome Sciences (United States)), David C. Linehan(University of Rochester), Vilmos Adleff(Johns Hopkins University), Jillian Phallen(Johns Hopkins University), Jeffrey A. Drebin(Memorial Sloan Kettering Cancer Center), Michael T. Barrett(Mayo Clinic in Arizona), Daniel D. Von Hoff(Translational Genomics Research Institute), Qing Kay Li(Johns Hopkins University), Sonya Parpart-Li(Human Genome Sciences (United States)), Siân Jones(Howard Hughes Medical Institute), Peter J. Allen(London School of Economics and Political Science), Ralph H. Hruban(Johns Hopkins University)
Cited by 484
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k